AMINOSYN 3.5% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMINOSYN 3.5% IN PLASTIC CONTAINER (AMINOSYN 3.5% IN PLASTIC CONTAINER).
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
| Metabolism | Amino acids are metabolized via transamination, deamination, and urea cycle in the liver; eliminated as CO2 and urea. |
| Excretion | Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%). |
| Half-life | The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis. |
| Protein binding | Amino acids are not significantly bound to plasma proteins; free fraction approaches 100%. |
| Volume of Distribution | Apparent volume of distribution for amino acids is approximately 0.3-0.5 L/kg, reflecting distribution into total body water and lean tissues. |
| Bioavailability | Intravenous: 100% (drug is administered as an IV infusion; no oral bioavailability due to hepatic first-pass metabolism). |
| Onset of Action | Intravenous infusion: Nitrogen balance improvement begins within 24-48 hours; plasma amino acid levels rise immediately during infusion. |
| Duration of Action | Duration of nitrogen retention effect is dependent on infusion rate and metabolic demand; effects last for hours post-infusion, but sustained benefit requires continuous or intermittent dosing. |
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
| Dosage form | INJECTABLE |
| Renal impairment | Contraindicated in severe renal impairment (GFR <25 mL/min) due to risk of uremia. In moderate impairment (GFR 25-50 mL/min), use with caution and reduce dose by 50%. Monitor serum BUN and creatinine. |
| Liver impairment | In Child-Pugh class B or C cirrhosis, avoid use due to risk of hepatic encephalopathy from amino acid load. In class A, use with caution and reduce dose by 50%. |
| Pediatric use | Intravenous infusion of 30-40 mL/kg/day (equivalent to 1.05-1.4 g amino acids/kg/day). Adjust based on nitrogen balance and growth. Monitor serum ammonia. |
| Geriatric use | Start at 30-50% of adult dose due to reduced renal function and metabolic rate. Increase slowly based on tolerance. Monitor for fluid overload and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMINOSYN 3.5% IN PLASTIC CONTAINER (AMINOSYN 3.5% IN PLASTIC CONTAINER).
| Breastfeeding | It is not known whether amino acids from Aminosyn are excreted in human breast milk. Due to lack of data, caution is advised. M/P ratio is not established. |
| Teratogenic Risk | Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic effects have been reported; however, maternal nutritional status may affect fetal development. Use during pregnancy only if clearly needed. No trimester-specific risks are identified. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Inborn errors of amino acid metabolism (e.g., maple syrup urine disease)","Severe hepatic failure with hyperammonemia","Severe metabolic acidosis"]
| Precautions | ["Risk of hyperammonemia, especially in patients with hepatic impairment","Monitor serum electrolytes, fluid balance, and acid-base status","Risk of infection from catheter use","Do not administer simultaneously with blood through same tubing due to risk of agglutination"] |
| Food/Dietary | No direct food interactions. Parenteral nutrition is used when oral intake is contraindicated. Ensure adequate caloric supplementation from other sources (e.g., dextrose, lipids) to prevent protein catabolism. |
Loading safety data…
| Monitor maternal nutritional status, electrolytes, renal function, and blood glucose. Fetal growth and well-being should be assessed by ultrasound if prolonged use in pregnancy. |
| Fertility Effects | No known effects on fertility. Amino acid supplementation is unlikely to impair reproductive function. |
| Clinical Pearls | Use only when oral/enteral nutrition is impossible or inadequate. Monitor serum electrolytes, BUN, and glucose regularly. Do not administer simultaneously with blood products via same IV line. Ensure central line placement for concentrations >10% due to high osmolarity; 3.5% can be given peripherally but monitor for phlebitis. |
| Patient Advice | This solution provides protein to help maintain muscle mass when you cannot eat normally. · Tell your healthcare provider if you have a history of liver or kidney disease. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · Do not stop the infusion abruptly unless instructed by your doctor. |